Atara Biotherapeutics Inc (NASDAQ: ATRA) stock suffered a major decline of -10.7% on 3/10/25. The shares closed at $6.16. However, trading volume in this decline was unusually low at 58% of normal. The stock has performed in line with the market over the last nine months and has declined -10.9% during the last week.
Current PriceTarget Research Rating
Atara Biotherapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment